Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune monitoring of belatacept versus tacrolimus in living-donor kidney transplant recipients
NL-OMON41595Phase 4Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2013
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of belatacept and tacrolimus in kidney transplant (2 arms), sponsored by Erasmus MC. Primary endpoints: Presence, frequency, and characteristics of effector CD4+ and CD8+ T cells, Treg suppressive activity and Treg characterization and 6 more. Started Oct 2013; status: active, not recruiting.
02
Drugs
belatacepttacrolimus
03
Conditions
kidney transplant
Beyond the preview
Go deeper on NL-OMON41595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41595.